{"filings":[{"id":667561,"accession_number":"0001832511-26-000026","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-26T20:06:05+00:00","items":["3.01","9.01"],"status":"ready","headline":"P3 Health Partners regains Nasdaq compliance on Listing Rule 5550(b)(2)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 20, 2026 confirming compliance with continued listing standards.","Compliance determination based on Company's Form 8-K filed May 15, 2026.","Previously disclosed non-compliance with Nasdaq Listing Rule 5550(b) on November 28, 2025.","Company now satisfies the $35 million market value of listed securities requirement under Rule 5550(b)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472596,"accession_number":"0001832511-26-000024","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-15T20:58:03+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"P3 Health Partners exchanges $252M debt for preferred stock, issues $30M Series D units to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged ~$252.5M of promissory notes (principal, accrued interest, fees) for non-convertible, non-voting preferred stock.","Issued $30M of Series D 19.5% Cumulative Preferred Stock + warrants to CPF as first tranche of up to $70M.","Believes it has regained compliance with Nasdaq minimum $2.5M stockholders' equity requirement; extension through May 20, 2026.","Pro forma total stockholders' equity improved from ($143.5M) to $82.1M after Debt Exchange and Series D issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442720,"accession_number":"0001832511-26-000021","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-14T20:10:41+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners reports Q1 net income $3M, raises FY 2026 adjusted EBITDA guidance to $20-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $386M (+4% YoY); net income $3M vs net loss $44.2M prior year.","Adjusted EBITDA $25.8M ($81 PMPM); cites contract restructuring and operational redesign.","At-risk membership ~106,000, down 10% YoY due to intentional network rationalization.","Full-year 2026 adjusted EBITDA guidance raised to $20-$60M (midpoint $40M).","Medical margin $73.7M; excluding prior-year development and settlements $56.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":386390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95997,"accession_number":"0001832511-26-000018","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"P3 converts ~$252.5M debt to preferred stock, raises $10M to regain Nasdaq equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Exchanged ~$252.5M promissory notes for Series A/B/C preferred stock (13.5%-19.5% dividends) to boost stockholders' equity.","Secured up to $70M in Series D preferred plus warrants from largest holder CPF; initial $10M tranche closed.","Standstill extended to Jan 1, 2027; CPF may designate independent director if ownership exceeds 40%.","Special committee negotiated transactions; intended to satisfy Nasdaq minimum equity requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109487,"accession_number":"0001832511-26-000010","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners reports Q4 net loss $165.7M, provides 2026 EBITDA guidance midpoint $10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $384.8M, net loss $165.7M, adjusted EBITDA loss $76.1M.","Full-year 2025 revenue $1.46B, net loss $323.1M, adjusted EBITDA loss $161.3M.","At-risk membership declined ~9% to ~115,000 in Q4 due to network realignment.","2026 guidance: adjusted EBITDA range -$20M to +$40M, midpoint $10M, ~$170M YoY improvement.","Normalized full-year adjusted EBITDA loss improved to $149.1M from $193.0M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109486,"accession_number":"0001832511-26-000006","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners enters Nebraska Medicare Advantage agreement with large nonprofit health insurer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 will provide clinical, operational, and data-driven support to primary care providers in client’s Nebraska Medicare Advantage network.","Management services fees for performance years 2026 and 2027; global risk arrangement for 2028 and beyond.","Master Services Agreement initial term through Dec 31, 2030, with automatic one-year renewal unless 180-day notice given.","Client may terminate SOW upon 90-day notice if P3 fails to meet agreed performance metrics for 2026 or if key persons depart.","If client opts not to pursue CMS Medicare Advantage bid for 2027-2028, SOW terminates with break-up fee covering actual costs plus direct termination costs, capped at an agreed amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109485,"accession_number":"0001832511-26-000005","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health extends $19M draw period on $40M promissory note tranche to June 30, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to existing $40M third tranche allows draws of remaining $19M through June 30, 2026.","Originally dated May 29, 2025; all other Note terms unchanged.","No new borrowing; simply extends draw availability on previously committed facility.","Counterparty is VBC Growth SPV 5, LLC (affiliate of Chicago Pacific Founders)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126004,"accession_number":"0001832511-25-000028","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"P3 Health Partners receives Nasdaq deficiency notice for failing to meet minimum stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Nov 21, 2025, Nasdaq notified P3 Health Partners that it lacks the $2.5M minimum stockholders' equity required by Listing Rule 5550(b)(1).","Company also does not meet the alternatives of market value of listed securities or net income from continuing operations.","Letter has no immediate delisting effect; company has 45 calendar days to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant an extension of up to 180 calendar days from Nov 21, 2025 to evidence compliance.","Company intends to submit a compliance plan and is pursuing steps to restore compliance, though no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126003,"accession_number":"0001832511-25-000024","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q3 revenue $345.3M (-5% YoY); adjusted EBITDA loss $45.9M; narrows guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["At-risk membership ~116k (-10% YoY) due to intentional network/payer rationalization.","Medical margin $4.4M ($13 PMPM) impacted by unfavorable mid-year settlement adjustments.","Adjusted EBITDA loss $45.9M ($132 PMPM); YTD normalized loss $70.1M ($67 PMPM).","FY 2025 guidance: revenue $1.4B-$1.45B; adjusted EBITDA loss $(110)M-$(95)M.","Identified $120M-$170M EBITDA expansion opportunity; targeting profitability in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-22.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1074266000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126002,"accession_number":"0001832511-25-000023","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners forms MSO JV with Commonwealth Primary Care ACO (80/20 split)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 subsidiary P3 ACO holds 80% interest; CPC ACO holds 20% in new MSO Delaware LLC.","MSO will manage ACO activities: shared services, financial mgmt, compliance, data analytics.","Management fee equals liabilities assumed plus fair-market-value margin; shared savings from 2026.","P3 ACO may redeem CPC ACO's interest after three years; CPC can force redemption if P3 fails to act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142736,"accession_number":"0001832511-25-000015","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners extends term loan interest-only period to Sep 2026; maturity to Dec 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest-only period extended to September 30, 2026; maturity extended to December 31, 2027.","Interest rate remains 12% through Dec 31, 2025, then increases to 15% after.","Principal payments reset to fixed $5 million per payment date following interest-only period.","Amendment replaces single PIK period with two: first (thru Dec 2024) 8% cash+4% PIK; second (Jan 2026-Dec 2027) 12% cash+3% PIK.","Lender representatives receive board observation rights at borrower's holding company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142735,"accession_number":"0001832511-25-000010","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q2 revenue down 6% YoY; adj. EBITDA loss $17.1M; FY guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Average at-risk membership ~115,000, down 9% YoY due to network/payer rationalization.","Revenue $355.8M (-6% YoY); medical margin $30.6M ($89 PMPM). Excl. prior-period adj., medical margin $39.3M.","Adjusted EBITDA loss $17.1M ($50 PMPM); excl. prior-period adj., loss was $8.5M ($25 PMPM).","FY 2025 guidance: revenue $1.35B-$1.5B, medical margin $124M-$154M, adj. EBITDA loss $69M-$39M.","Identified $120M-$170M in additional EBITDA opportunities; three of four markets EBITDA positive/breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":729013000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142734,"accession_number":"0001628280-25-034559","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"P3 Health Partners appoints CEO Aric Coffman to board after Dr. Abdou resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sherif Abdou resigned from the Board effective July 2, 2025; transition services agreement expired April 30, 2025.","Dr. Aric Coffman, CEO of P3 Health Partners, appointed as Class I director effective July 8, 2025, term expiring 2028.","Dr. Coffman is not independent due to his CEO role; he will not serve on any Board committees.","Dr. Coffman will not receive additional compensation for board service.","Board unanimously approved appointment on recommendation of Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160814,"accession_number":"0001628280-25-030297","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners shareholders elect three Class I directors, approve auditor and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sherif Abdou, Greg Kazarian, Greg Wasson elected as Class I directors with >209M votes each.","BDO USA ratified as independent auditor for FY2025; 232M votes for, 690K against.","Advisory vote on executive compensation passed with 211.8M votes for.","Issuance of up to 1,428,129 shares upon warrant exercise by VBC Growth SPV 4, LLC approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160813,"accession_number":"0001628280-25-029146","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures up to $70M unsecured promissory note at 19.5% interest, issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First tranche $15M drawn; second $15M due by June 22, 2025; third $40M mutually agreed by Dec 31, 2025.","Note matures Aug 13, 2028; interest 19.5% p.a. (11.5% PIK option); default rate adds 4%.","Warrants for 1,430,281 shares at $7.39/share exercisable after Nasdaq stockholder approval; terminate May 29, 2032.","Back-end fee ranges from 2.25% to 9% depending on repayment date; proceeds for working capital.","Approved by independent committee; VBC 5 is affiliate of principal stockholder (Chicago Pacific Founders)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160812,"accession_number":"0001628280-25-025928","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q1 revenue down 4%, medical margin hit by $23M prior-year claims adjustment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $373.2M, down 4% YoY; average at-risk membership 115,900 (-8%).","Medical margin $17.2M vs $36.6M prior year; includes negative $23M net impact from prior-year claims from one payer.","Adjusted EBITDA loss $22.2M vs $19.8M loss prior year; includes negative $9M prior claims and retroactive adjustments.","FY2025 guidance affirmed: revenue $1.35B-$1.5B, medical margin $174M-$210M, Adj. EBITDA -$35M to $5M.","CEO says turnaround ahead of schedule; 3 of 4 markets achieved breakeven or better in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":373225000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160811,"accession_number":"0001628280-25-018083","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"P3 Health Partners effects 1-for-50 reverse stock split effective April 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split applied to Class A and Class V common stock at a 1-for-50 ratio.","No fractional shares issued; stockholders receive cash in lieu based on closing price.","Proportional adjustments made to equity awards, warrants, and incentive plans.","Class A common stock began trading split-adjusted on April 14, 2025 under symbol 'PIII'.","New CUSIP for Class A common stock is 744413 204; warrants CUSIP unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160810,"accession_number":"0001628280-25-016833","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"P3 Health Partners announces 1-for-50 reverse stock split effective April 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at March 31 special meeting; board set ratio at 1-for-50.","Reverse split effective 5:00 p.m. ET on April 11; split-adjusted trading begins April 14 under PIII.","No fractional shares issued; cash payment for fractional shares based on closing price on effective date.","Warrants continue under PIIIW with same CUSIP; adjustments to equity awards and warrants.","New CUSIP for Class A common stock: 744413 204."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160809,"accession_number":"0001628280-25-016337","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners shareholders approve reverse stock split at 1:10-1:60 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting held March 31, 2025; both proposals approved by stockholders.","Proposal 1 (reverse stock split): 227,773,176 FOR, 9,377,137 AGAINST, 10,925 abstain.","Proposal 2 (adjournment): 227,648,046 FOR, 9,484,329 AGAINST, 28,863 abstain.","Board to set final ratio between 1:10 and 1:60 and announce timing.","No other matters voted on at the Special Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179010,"accession_number":"0001628280-25-015165","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners FY2024 net loss widens to $310.4M; revenue up 18% to $1.50B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net loss $310.4M vs $186.4M prior; adjusted EBITDA loss $167.2M vs $85.5M.","Q4 net loss $129.1M vs $69.1M; medical margin fell 37% to $85.5M for the year.","At-risk membership grew 14% to 123,800; total revenue $1.50B (+18% YoY).","FY2025 guidance: revenue $1.35B-$1.50B, adjusted EBITDA loss ($35M)-$5M, at-risk members 109k-119k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179009,"accession_number":"0001628280-25-005930","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures $30M loan at 19.5% interest, issues warrants for 71.4M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M unsecured promissory note from VBC Growth SPV 4 (affiliate of principal stockholder), drawn in two $15M tranches.","Interest at 19.5% per annum; company may pay 8% cash + 11.5% PIK or all in-kind if subordination restricts cash.","Warrants to buy 71,406,480 shares at $0.2068 per share, exercisable only after stockholder approval sought at 2025 annual meeting.","Maturity August 13, 2028; up-front fee 1.5% of $30M; back-end fee up to 9.0% depending on repayment timing.","Proceeds fund working capital; note is subordinated to existing CRG term loan facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179008,"accession_number":"0001628280-25-005308","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"P3 Health Partners provides preliminary 2025 guidance; proposes $30M note from largest shareholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2025 revenue guidance of $1.35B-$1.5B; Adjusted EBITDA of $(35)M to $5M.","At-risk members guidance of 108k-118k for FY2025.","Proposed $30M unsecured promissory note and warrants from largest shareholder, terms similar to Dec 2024 financing.","CEO states $130M+ EBITDA growth initiatives on track; targeting profitability in 2025.","Full 2025 guidance to be issued with Q4 2024 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195694,"accession_number":"0001628280-24-051677","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures $25M financing from affiliate with 71.4M warrants at $0.2137/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 LLC subsidiary entered a $25M unsecured promissory note with VBC 3 at 19.5% interest, maturing June 30, 2028.","Warrants to purchase 71,406,480 shares of common stock at $0.2137 per share issued to VBC 3.","Refinanced existing 2022 loan with VBC 1 at 0.5% lower interest; back-end fee waived.","Proceeds to fund working capital; CPF standstill extended through January 1, 2026.","Note subordinated to existing term loan; interest may be paid in-kind under subordination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195693,"accession_number":"0001628280-24-047123","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Q3 revenue $362.1M (+26% YoY) but net loss widens to $102.9M; withdraws FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $362.1M, up 26% YoY; capitated revenue $357.7M (+25%).","Net loss $102.9M vs $37.3M loss in Q3 2023; Adjusted EBITDA loss $71.0M.","Medical margin nearly zero at $0.5M vs $36.2M prior year; gross profit loss $39.8M.","Withdraws FY2024 guidance due to lower risk adjustment, prior negative developments, elevated medical costs.","CEO highlights $130M+ potential improvement opportunities; demand for platform remains strong."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1129769000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211960,"accession_number":"0001628280-24-038802","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"P3 Health Partners names Leif Pedersen as CFO effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leif Pedersen appointed CFO effective October 1, 2024; succeeds Atul Kavthekar, who resigned.","Kavthekar's resignation not due to any disagreement; he will serve as advisor post-transition.","Pedersen most recently VP Finance at UnitedHealth Group-Optum Health; previously at DaVita.","Compensation: $440K base salary, 50% target bonus, equity grants of 1.5M shares (options + RSUs).","Severance: 6 months base salary if terminated without cause after 6 months, subject to mitigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211959,"accession_number":"0001628280-24-035600","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q2 revenue up 15% to $379.2M; net loss widens to $28.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $379.2M (+15% YoY); capitated revenue $374.3M (+15% YoY).","Gross profit $14.0M (down from $26.8M); medical margin $41.1M (down from $50.5M).","Net loss $28.8M (vs $27.6M); Adjusted EBITDA loss $8.8M (vs +$0.2M).","FY2024 guidance: revenue $1.45-$1.55B; medical margin $230-$250M; Adjusted EBITDA $20-$40M.","CEO cites top-line growth and balance sheet improvement from capital raise."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":767645000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230774,"accession_number":"0001628280-24-027325","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners annual meeting elects three directors, ratifies auditor, approves executive compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class III directors: Jeffrey G. Park, Thomas E. Price, Mary Tolan, with votes ranging from 187M to 189M for.","Ratified BDO USA as independent auditor for FY2024 with 200.6M votes for, 110K against.","Advisory approval of named executive officer compensation with 191.5M for, 294K against.","Approved 'ONE YEAR' frequency for future advisory votes on executive compensation (166.3M for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230773,"accession_number":"0001104659-24-065141","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"P3 Health Partners raises $42.2M in private placement of 67.4M units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~67.4M units at ~$0.6270 each; each unit = 1 share Class A + 1 warrant (exercise $0.5020, 7-year term).","Gross proceeds ~$42.2M; pre-funded warrants used in lieu of shares for some institutional investors.","Chicago Pacific Partners purchased ~31.9M units ($20M); standstill restriction extended to July 31, 2025.","CPF gets board designation rights for one independent director if it holds 40% of outstanding common stock.","Registration rights agreement filed; company to register resale of shares and warrant shares within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230772,"accession_number":"0001104659-24-064559","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"P3 Health Partners raises ~$42.2M via private placement of ~67.4M units at $0.627/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$42.2M; each unit priced at ~$0.6270, closing expected May 24, 2024.","Each unit comprises one Class A share and a warrant (exercise $0.5020, 7-year term).","Institutional investors may opt for pre-funded warrants at $0.0001 per share.","CPF purchased ~31.9M units for ~$20M; standstill extended to July 31, 2025.","CPF gains board designation rights if it holds 40% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230771,"accession_number":"0001628280-24-024334","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"P3 Health Partners receives Nasdaq bid price deficiency notice; 180-day cure period ends Nov 11, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 15, 2024 for common stock (PIII) bid price below $1.00 for 31 straight business days.","Must close at $1.00 or higher for at least 10 consecutive business days by November 11, 2024 to regain compliance.","If not compliant by Nov 11, may qualify for an additional 180-day period if other listing standards are met.","Stock remains listed for now; company will evaluate available options to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230770,"accession_number":"0001628280-24-022303","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"P3 Health Partners appoints Dr. Aric Coffman as CEO, replacing Dr. Sherif Abdou effective May 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Coffman receives $750K base salary, 75% target bonus, and equity awards covering 16.5M shares (12.1M options, 4.4M RSUs).","Outgoing CEO Dr. Abdou becomes Vice Chair of Board and Senior Advisor under consulting agreement for $400K fee through April 2025.","Board adopts 2024 Employment Inducement Incentive Award Plan reserving 16.5M shares for inducement grants.","Dr. Coffman previously CEO of Honest Medical Group; held leadership roles at DaVita Medical Group and Optum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230769,"accession_number":"0001628280-24-021663","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q1 revenue up 29% to $388.5M; appoints Dr. Aric Coffman as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $388.5M (+29% YoY); capitated revenue $384.1M; net loss improved to $49.6M from $52.4M.","Medical margin $36.6M vs $39.2M prior year; gross profit fell to $6.4M from $16.5M.","Reaffirms FY2024 guidance: revenue $1.45-1.55B, medical margin $230-250M, adjusted EBITDA $20-40M.","Dr. Aric Coffman appointed CEO; company anticipates reaching adjusted EBITDA positive in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":388488000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}